Table 2.
Hypoxia-targeted clinical trials in pancreatic cancer
| Categories | Interventions | Pancreatic Cancer Types | Phases | Status | NCT Number |
|---|---|---|---|---|---|
| Vascular normalizing agent | OXY111A (ITPP) | Pancreatic Neoplasms | I, II | N/A | NCT02528526 |
| Chemoradiotherapy (CRT) (nab-paclitaxel, Capecitabine, Gemcitabine, high/low dose of radiation) ± Nelfinavir | Pancreatic Neoplasms (Locally Advanced Non-metastatic) | I, II | Recruiting | NCT02024009 | |
| Cediranib/Cediranib Maleate + Olaparib | Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Unresectable Pancreatic Carcinoma | II | Recruiting | NCT02498613 | |
| Antiangiogenic agent | Bevacizumab (Anti-VEGF monoclonal antibody) + Capecitabine + Radiation | Locally Advanced Pancreatic Cancer | I | Completed | NCT00047710 |
| Sorafenib + Gemcitabine | Pancreatic Cancer, Adenocarcinoma of the Pancreas | I | Completed | NCT00375310 | |
| Hypoxia-activated prodrug | TH-302 (Evofosfamide) + Gemcitabine/ Docetaxel/Pemetrexed | Pancreatic Cancer | I, II | Completed | NCT00743379 |
| Gemcitabine + TH-302/Placebo | Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | III | Completed | NCT01746979 | |
| TH-302 + Sunitinib | Pancreatic Neuroendocrine Tumors | I | N/A | NCT01381822 | |
| TH-302 + Ipilimumab | Metastatic Pancreatic Cancer | I | N/A | NCT03098160 | |
| Inhibition of HIF-1α | Digoxin + FOLFIRINOX (5-Fluorouracil, Calcium Leucovorin, Irinotecan, Oxaliplatin) | Pancreas Cancer; Adenocarcinoma of the Pancreas | II | Not yet recruiting | NCT04141995 |
| Photodynamic therapy | EF5 (a surrogate marker for hypoxia) + Motexafin Lutetium (photosensitizing drug) | Recurrent and Stage I to IV Pancreatic Cancer | N/A | Terminated | NCT00087191 |
The italics in the “Interventions” column represent drugs used for hypoxia-based therapeutic strategies. N/A, not available